VCYT

SEC source: 0001384101-21-000184 · wf-form4_164003664535663.xml · nonDerivative · entry 1

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,720

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 17, 2021.

SEC source: 0001384101-21-000182 · wf-form4_163917252474255.xml · derivative · entry 3

Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,844

Underlying: Common Stock · 11,286 shares

Expires 2025-03-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option is fully vested.

SEC source: 0001384101-21-000182 · wf-form4_163917252474255.xml · nonDerivative · entry 1

Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 73,542

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · derivative · entry 13

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,750 shares

Expires 2030-05-10

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F8 · derivative.exercise_date: The option is fully vested.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · derivative · entry 12

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,375

Underlying: Common Stock · 4,375 shares

Expires 2030-03-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F7 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuousservice thereafter.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 9

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,912

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 8

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,662

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 7

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 54,037

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 6

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 52,287

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · derivative · entry 11

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,750

Underlying: Common Stock · 3,750 shares

Expires 2029-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · derivative · entry 10

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 4,407

Underlying: Common Stock · 4,406 shares

Expires 2028-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 5

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,912

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $36.88 to $37.66. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 4

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,697

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.79 to $36.74. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 3

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,594

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $34.70 to $35.70. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 2

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,144

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000180 · wf-form4_163899971487247.xml · nonDerivative · entry 1

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 53,394

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000178 · wf-form4_163882960714591.xml · nonDerivative · entry 1

Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 62,256

F1 · kind: The reporting person is reporting the withholding of 738, 738 and 812 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,875, 1,875 and 2,062 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person.

SEC source: 0001384101-21-000176 · wf-form4_163882945893577.xml · nonDerivative · entry 1

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,988

F1 · kind: The reporting person is reporting the withholding of 292, 248 and 372 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587, 500 and 750 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person.

SEC source: 0001384101-21-000163 · wf-form4_163597436143646.xml · nonDerivative · entry 3

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By IRA

Disclosed balance after: 0

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020.

F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $49.35 to $49.53. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000163 · wf-form4_163597436143646.xml · nonDerivative · entry 2

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By IRA

Disclosed balance after: 1,241

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020.

F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $48.30 to $49.29. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000163 · wf-form4_163597436143646.xml · nonDerivative · entry 1

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By IRA

Disclosed balance after: 4,200

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020.

F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $47.25 to $47.89. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000161 · wf-form4_163597419799661.xml · nonDerivative · entry 1

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,900

F1 · kind: The reporting person is reporting the withholding of 149 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 300 Restricted Stock Units, respectively, granted on May 11, 2020, and does not represent a sale by the reporting person.

SEC source: 0001384101-21-000159 · wf-form4_163225552291274.xml · nonDerivative · entry 1

Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman

10b5-1 filing: Not disclosed

Ownership: Indirect · The Bonnie H. Anderson Living Trust

Disclosed balance after: 217,478

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2021.

F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.40. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000157 · wf-form4_163165186122017.xml · nonDerivative · entry 1

Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman

10b5-1 filing: Not disclosed

Ownership: Indirect · The Bonnie H. Anderson Living Trust

Disclosed balance after: 220,078

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 9, 2021.

F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $50.00 to $50.08. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 6

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,049

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · derivative · entry 9

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,750

Underlying: Common Stock · 4,375 shares

Expires 2030-03-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · derivative · entry 8

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 3,750 shares

Expires 2029-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · derivative · entry 7

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,813

Underlying: Common Stock · 4,406 shares

Expires 2028-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F4 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 5

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,975

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $51.07 to $51.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 4

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,472

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $50.06 to $51.06. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 3

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 63,506

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 2

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 59,131

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000155 · wf-form4_163122163694896.xml · nonDerivative · entry 1

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 55,381

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 11, 2021.

SEC source: 0001384101-21-000150 · wf-form4_163104909320686.xml · nonDerivative · entry 1

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,975

F1 · kind: The reporting person is reporting the withholding of 292, 248 and 372 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 588, 500 and 750 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person.

SEC source: 0001384101-21-000148 · wf-form4_163104889655603.xml · nonDerivative · entry 1

Anderson Bonnie H · CIK 0001588970 · Director · Executive Chairwoman

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 64,544

F1 · kind: The reporting person is reporting the withholding of 738, 738 and 812 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 1,875, 1,875 and 2,063 Restricted Stock Units, respectively, granted on March 2, 2018, February 28, 2019 and February 28, 2020 respectively, and does not represent a sale by the reporting person.

SEC source: 0001384101-21-000146 · wf-form4_162810834688133.xml · nonDerivative · entry 2

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By IRA

Disclosed balance after: 4,400

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020.

F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $44.07 to $44.81. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000146 · wf-form4_162810834688133.xml · nonDerivative · entry 1

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By IRA

Disclosed balance after: 5,954

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on November 25, 2020.

F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.03 to $44.00. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000127 · wf-form4_162681424157518.xml · derivative · entry 2

Chambers Rebecca · CIK 0001823563 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,000

Underlying: Common Stock · 67,000 shares

Expires 2031-07-19

F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on July 19, 2022, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

SEC source: 0001384101-21-000127 · wf-form4_162681424157518.xml · nonDerivative · entry 1

Chambers Rebecca · CIK 0001823563 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 34,000

F1 · kind: Restricted stock units (RSUs) awarded on July 19, 2021, which vest 25% on September 2, 2022 and 1/16 on each quarterly anniversary thereafter subject to continuing employment of the Reporting Person on each vesting date.

SEC source: 0001384101-21-000116 · wf-form4_162465194522576.xml · derivative · entry 3

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 48,125

Underlying: Common Stock · 4,375 shares

Expires 2030-03-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.

F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

SEC source: 0001384101-21-000116 · wf-form4_162465194522576.xml · nonDerivative · entry 2

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,887

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.

F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $39.69 to $39.84. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.

SEC source: 0001384101-21-000116 · wf-form4_162465194522576.xml · nonDerivative · entry 1

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,262

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on June 12, 2020.

SEC source: 0001384101-21-000112 · wf-form4_162335626936965.xml · nonDerivative · entry 1

Holstein Jens · CIK 0001819880 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,720

F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

SEC source: 0001384101-21-000111 · wf-form4_162335616180777.xml · nonDerivative · entry 1

JONES EVAN/ FA · CIK 0001020741 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,720

F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

SEC source: 0001384101-21-000114 · wf-form4_162335648610256.xml · nonDerivative · entry 1

EPSTEIN ROBERT S · CIK 0001252004 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,720

F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

SEC source: 0001384101-21-000109 · wf-form4_162335584509410.xml · nonDerivative · entry 1

EASTHAM KARIN · CIK 0001231845 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,720

F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

SEC source: 0001384101-21-000110 · wf-form4_162335591682903.xml · nonDerivative · entry 1

BISHOP JOHN L · CIK 0001189846 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,720

F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

SEC source: 0001384101-21-000113 · wf-form4_162335639984759.xml · nonDerivative · entry 1

GORDON KEVIN K · CIK 0001218483 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,720

F1 · kind: Restricted stock units awarded on June 8, 2021 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.

SEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · derivative · entry 7

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 26,250

Underlying: Common Stock · 3,750 shares

Expires 2029-02-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F6 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2020, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.

SEC source: 0001384101-21-000101 · wf-form4_162318467981821.xml · derivative · entry 6

Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,219

Underlying: Common Stock · 4,406 shares

Expires 2028-03-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter